GET DAILY SIGNALSWhy Is Zymeworks (ZYME) Stock Down -5.74% Today?
Key Takeaways
- ZYME shares slid about 5.74% to $27.40, extending a sharp pullback from a 52-week high near $31.97 touched earlier this week.
- The move is best characterized as profit-taking after a powerful post-earnings rally, rather than any new negative corporate announcement.
- Third-quarter results, reported after the close on November 9, were driven largely by a one-time $250 million Jazz Pharmaceuticals milestone tied to Ziihera's FDA approval — income that analysts describe as nonrecurring.
- Earlier catalysts, including raised 2026 guidance and a Roche collaboration on ZW209, remain intact but failed to halt the selling.
- The pullback aligns with broader weakness across small- and mid-cap biotechnology peers, where several recent winners also gave back gains.
- Traders are watching the 50-day moving average near $27.50 and any update on Hart-Scott-Rodino clearance for the Roche deal.
- For deeper context on valuation and expectations, explore Price Targets, Earnings, and Forecast pages.
- To see how automated strategies are positioning around names like this, visit Trending AI Robots.
Opening Summary
Zymeworks Inc. (ZYME), a clinical-stage biopharmaceutical company that develops multifunctional biotherapeutics — including bispecific antibodies and antibody-drug conjugates — for cancer and other diseases, moved sharply lower in Thursday's session. The stock fell roughly 5.74% to $27.40, down from a prior close of $29.07. The decline extended a sell-off that began the previous session, when shares dropped about 7.6%, and comes despite a wave of recently positive news around the company's earnings, raised guidance, and new partnerships. Market participants attributed the move primarily to profit-taking and concern that a large portion of the company's recent earnings was nonrecurring in nature.
Profit-Taking After a Post-Earnings Rally
The most immediate driver behind ZYME's decline appears to be simple profit-taking. The stock had staged a rapid advance after its third-quarter report on November 9, which showed revenue of $256.5 million — up sharply year over year and well above consensus — alongside a swing to profitability. The company also raised its full-year 2026 revenue guidance to a range of $337 million to $351 million and lifted its adjusted EBITDA outlook. Those headlines, combined with analyst price-target increases from firms including TD Cowen, Truist, and H.C. Wainwright, propelled the shares toward a 52-week high near $31.97. After such a run, traders often lock in gains, particularly when a stock trades at a stretched valuation relative to book value.
Concerns Over the Quality of Recent Earnings
A second, more fundamental factor is the composition of the company's latest results. A substantial share of third-quarter revenue and profit stemmed from a $250 million milestone payment received from Jazz Pharmaceuticals following U.S. FDA approval of Ziihera for first-line HER2-positive gastroesophageal adenocarcinoma. While unquestionably positive for the business, this milestone is a one-time item. Analysts have flagged that much of the quarter's profitability is nonrecurring, and that recurring revenue from commercial products and royalties remains comparatively modest. This nuance has given some investors reason to reassess how much of the recent share-price appreciation is supported by durable earnings power.
Broader Biotech Sector Weakness
ZYME's pullback also coincides with a broader retreat across smaller-cap biotechnology names, where several recent momentum leaders gave back gains in tandem. When speculative, catalyst-driven biotech stocks cool off in unison, individual names often move more dramatically than the overall market. This sector-wide softness amplified the selling pressure in ZYME, even in the absence of any company-specific negative headline on the day.
Market Context and Trading Activity
The decline pushed ZYME toward its 50-day moving average, a widely followed short-term technical level situated near $27.50, after the stock failed to hold gains near its 52-week high. The pullback came on the heels of the prior session's 7.6% drop, indicating a swift unwind of the recent rally rather than a gradual drift. While intraday volume data remains incomplete, the sharp, back-to-back declines suggest elevated turnover relative to the recent pattern as investors reprice the shares. The move was more pronounced than the broader market's performance, consistent with a stock-specific and sector-driven correction rather than a broad index-led sell-off.
What Comes Next for ZYME
Looking ahead, investors will monitor whether ZYME can stabilize around key technical support levels and whether selling pressure in the biotech sector eases. Several forward catalysts remain on the calendar, including an R&D Day planned for February 2027 and additional data presentations from the company's pipeline programs. The closing of the Roche collaboration for ZW209, which remains subject to regulatory clearance, is another milestone that could influence sentiment. Risks include continued volatility tied to clinical data readouts, dependence on milestone and royalty income rather than steady product revenue, and the broader appetite for speculative biotech names. As always, near-term price action may hinge as much on market sentiment as on fundamental developments.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots that are performing strongly under current market conditions. Tickeron offers hundreds of automated trading bots covering thousands of tickers, but only the strongest performers are featured in this dedicated section. The bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of approaches to explore. If you are interested in how algorithmic strategies are navigating volatile biotech names, consider reviewing the Trending AI Robots page to see what is currently leading the field.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ZYME's Stochastic Oscillator dives oversold zone
The Stochastic Oscillator for ZYME moved into oversold territory on November 13, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for ZYME crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Following a +6.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZYME advanced for three days, in 252 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
ZYME may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 191 of 221 cases where ZYME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The 10-day RSI Indicator for ZYME moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 53 similar instances where the indicator moved out of overbought territory. In 42 of the 53 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ZYME as a result. In 55 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.
The Moving Average Convergence Divergence Histogram (MACD) for ZYME turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 37 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
ZYME moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZYME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. ZYME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (26.452) is normal, around the industry mean (3.498). P/E Ratio (-14.668) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (52.910) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZYME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company for cancer & autoimmune treatment
Industry Biotechnology
Advertisement